Adc Therapeutics SA Aktie News

Nettoverkaufserlöse im zweiten Quartal 2026 in Höhe von 18,6 Mio. USD; Zahlungsmittel und Zahlungsmitteläquivalente in Höhe von 219,1 Mio. USD zum 30. Juni 2026 LOTIS‑7, LOTIS‑5 und MZL IIT‑Daten zur Präsentation bei ASH eingereicht Unternehmen bewertet regulatorischen Weg für ZYNLONTA® zur Erlangung der vollen Zulassung und zum Vorstoß in frühere Linien von DLBCL nach dem LOTIS‑5 Pre‑sBLA‑Meet...

LAUSANNE, Schweiz, 1. Juli 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), ein weltweit führendes und wegweisendes Unternehmen im Bereich Antikörper-Wirkstoff-Konjugate (ADCs) in der kommerziellen Phase, gab heute bekannt, dass das Unternehmen einem neuen Mitarbeiter am 1. Juli 2026 eine Zuteilung von Optionen zum Erwerb von insgesamt 17.000 Stammaktien des Unternehmens gewährt hat ("Gra...

100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab Full data expected in fourth quarter of 2026 LAUSANNE, Switzerland, June 30, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in the LOTIS-7 Phase 1b open-label ...

Planned ~17% workforce reduction expected to generate annualized estimated savings of approximately $10M, enhancing financial flexibility Company focused on delivering upcoming regulatory and clinical milestones, including planned LOTIS-5 sBLA submission and full LOTIS-7 data by end of 2026 LAUSANNE, Switzerland, June 24, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage...

ADC Therapeutics shares slumped nearly 53% in premarket trading on Thursday after a late-stage study testing its blood cancer drug showed more deaths among ​treated patients, despite meeting its main goal of improving progression-free survival.

Company to host conference call today at 4:30 p.m. EDT LAUSANNE, Switzerland, June 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end First quarter 2026 net product revenue of $20.0 million Cash and cash equivalents of $231.0 million as of March 31, 2026, with an expected cash runway at least into 2028 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, May 4, 2026 /PRNewswire/...